Clinoscope Services Limited has increased its stake in Nigerian pharmaceutical company, Neimeth International Pharmaceuticals Plc, after purchasing an additional 40 million ordinary shares valued at ₦312 million.
The acquisition, executed at ₦7.80 per share, was completed on August 4, 2026, in Lagos, according to a corporate disclosure filed with the Nigerian Exchange (NGX).
The disclosure was signed by Neimeth’s Company Secretary, Chinenye S. Adekanmbi.
Following the latest transaction, Clinoscope’s holding in Neimeth rose from 552,975,860 shares to 592,975,860 shares, reinforcing its position as one of the company’s major institutional shareholders.
The purchase comes at a significant period for Neimeth, which has been pursuing measures to strengthen its balance sheet, improve its financial position and raise additional capital to support its operations and expansion plans.
Clinoscope Rebuilds Neimeth Stake
The latest acquisition is particularly notable because it comes less than a year after Clinoscope embarked on a major sell-off of its Neimeth holdings.
In 2025, the investment company disposed of a combined 515.3 million Neimeth shares through two separate transactions.
The first disposal involved 15.3 million shares sold at ₦6.10 each on September 17, 2025.
A much larger transaction followed on December 19, 2025, when Clinoscope sold 500 million shares at ₦6.00 per share.
The 40 million shares acquired this month therefore represent a partial return to the company after the substantial reduction in its holding last year.
Measured against the 515.3 million shares sold during the 2025 divestment programme, the latest purchase amounts to approximately 7.8 per cent of the shares previously disposed of.
The move could be viewed by market watchers as renewed confidence in Neimeth’s prospects, particularly as the pharmaceutical company continues to implement measures aimed at improving its financial and operational position.
Neimeth Shares Gain 48% In 2026
Clinoscope’s latest purchase also comes against the backdrop of a strong performance in Neimeth’s share price this year.
The company’s stock closed at ₦8.60 on Friday, compared with ₦5.80 at the end of 2025.
That represents a year-to-date increase of approximately 48.28 per cent.
The appreciation means the shares are now trading above the ₦7.80 price at which Clinoscope executed its latest acquisition.
While share-price performance alone does not establish the reason for an investment decision, the timing of the purchase places the transaction within a period of considerable movement in Neimeth’s market value.
For an existing major shareholder to increase its position after previously reducing its exposure is also notable from an investor-confidence perspective.
Company Pursues ₦50bn Fundraising Programme
The latest share acquisition comes as Neimeth continues with a broader capital-strengthening strategy.
The pharmaceutical company recently undertook a capital restructuring exercise designed to address retained losses and improve the structure of its balance sheet.
Under the restructuring programme, Neimeth reduced its share premium account from ₦2.38 billion to ₦390.02 million and transferred ₦1.99 billion to its retained earnings reserve.
The company has also secured approval for a significantly expanded fundraising programme.
At its 67th Annual General Meeting in June 2026, shareholders approved an additional ₦30 billion capital-raising mandate.
The approval increased Neimeth’s overall fundraising mandate to ₦50 billion.
The new mandate builds on a ₦20 billion capital-raising programme approved by shareholders in June 2025.
Under that earlier programme, Neimeth raised approximately ₦2.44 billion through a rights issue, leaving about ₦17.56 billion of the original mandate unused.
The expanded fundraising authority gives the company additional room to pursue its capital requirements as it works to strengthen its business and support future growth.
Neimeth Returns To Profit
Neimeth’s recent financial performance also provides important context for the latest investment.
For the financial year ended December 31, 2025, the pharmaceutical manufacturer reported a pre-tax profit of ₦1.49 billion.
The result represented a significant turnaround from the ₦854.43 million pre-tax loss recorded in 2024.
One of the factors supporting the improvement was the company’s foreign exchange position.
Neimeth recorded a foreign exchange gain of ₦48 million in 2025, compared with a loss of more than ₦2 billion in the previous year.
The improvement in foreign exchange performance contributed to the company’s stronger bottom-line result and formed part of a wider recovery in its financial performance.
The company has been led by Managing Director, Pharm. Valentine C. Okelu, as it continues to navigate the challenges and opportunities within Nigeria’s pharmaceutical industry.
What The Latest Purchase Means
Clinoscope’s latest transaction is significant because it combines a sizeable share purchase with a reversal, albeit partial, of its previous reduction in Neimeth exposure.
The 40 million shares acquired for ₦312 million take Clinoscope’s total holding to nearly 593 million shares.
Although the transaction represents only a fraction of the shares sold by Clinoscope in 2025, it marks a clear increase in its stake following last year’s large-scale disposals.
The development also coincides with Neimeth’s efforts to improve its balance sheet, raise fresh capital and build on its return to profitability.
For investors following Neimeth, the combination of the increased institutional holding, the company’s 2025 return to profit, its capital restructuring programme and the expansion of its fundraising mandate will remain important developments to watch.
The immediate market response to Clinoscope’s acquisition will also provide further insight into how investors assess the pharmaceutical company’s ongoing recovery and growth strategy.
For now, the August 4 purchase places Clinoscope back in a stronger position within Neimeth’s shareholder structure, while the pharmaceutical manufacturer continues its efforts to consolidate its financial recovery and pursue its longer-term expansion plans.